APRINOIA THERAPEUTICS
APRINOIA is a late-stage biotechnology company committed to protecting patients' brain health and changing outcomes of neurodegenerative diseases through first-in-class and best-in-class diagnostic tools and novel therapies. The company aims to bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau, alpha-synuclein and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as Alzheimer's and Parkinson's Diseases. The company currently has operations in Hong Kong, Suzhou, Shanghai, Tokyo, and Boston.
APRINOIA THERAPEUTICS
Industry:
Biotechnology Health Diagnostics Medical Therapeutics
Founded:
2015-05-20
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.aprinoia.com
Total Employee:
11+
Status:
Active
Contact:
+1-617-225-4415
Email Addresses:
[email protected]
Total Funding:
61.93 M USD
Technology used in webpage:
Euro HSTS Microsoft DigiCert SSL Microsoft Azure Wix Media GeoTrust SSL Constant Hosting Microsoft Azure Asia East Region
Similar Organizations
Aardvark Therapeutics
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Applied Immune Technologies
Applied Immune Technologies is focused on developing therapeutic molecules for cancer, viral, and autoimmune diseases.ย
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Prose Biosystems
biotechnology, therapeutics
Regend Therapeutics
Regend Therapeutics focuses on the human organ regenerative medicine business
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Current Advisors List
Current Employees Featured
Founder
Investors List
Alzheimer's Drug Discovery Foundation
Alzheimer's Drug Discovery Foundation investment in Venture Round - APRINOIA Therapeutics
IMM Private Equity
IMM Private Equity investment in Series C - APRINOIA Therapeutics
KTB Network
KTB Network investment in Series C - APRINOIA Therapeutics
Yantai Dongcheng Pharmaceutical
Yantai Dongcheng Pharmaceutical investment in Series C - APRINOIA Therapeutics
KTB Network
KTB Network investment in Series B - APRINOIA Therapeutics
DCI Partners
DCI Partners investment in Series B - APRINOIA Therapeutics
TaiAn Technologies
TaiAn Technologies investment in Series B - APRINOIA Therapeutics
ShangPharma
ShangPharma investment in Series B - APRINOIA Therapeutics
Company K Partners
Company K Partners investment in Series A - APRINOIA Therapeutics
IMM Investment
IMM Investment investment in Series A - APRINOIA Therapeutics
Official Site Inspections
http://www.aprinoia.com Semrush global rank: 5.61 M Semrush visits lastest month: 1.29 K
- Host name: cloudproxy10054.sucuri.net
- IP address: 192.124.249.54
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "APRINOIA Therapeutics"
APRINOIA Therapeutics - Crunchbase Company Profile & Funding
Organization. APRINOIA Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... APRINOIA is a late-stage โฆSee details»
Org Chart Aprinoia Therapeutics - The Official Board
Organizational Chart of Aprinoia Therapeutics. Aprinoia Therapeutics www.aprinoia.com +86 886 2265 5886; Add an executive. Aprinoia Therapeutics News . Anything missing? We search for โฆSee details»
APRINOIA Therapeutics Inc. (APRI) Company Profile & Overview
Oct 28, 2024 APRINOIA Therapeutics is a clinical-stage biotechnology company committed to protecting patientsโ brain health and changing clinical outcomes for a broad range of โฆSee details»
Aprinoia Therapeutics Company Profile 2024: Valuation, Funding ...
Aprinoia Therapeutics General Information Description. Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing โฆSee details»
APRINOIA Therapeutics โ A clearer picture, a brighter tomorrow.
At APRINOIA, we bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau, ฮฑ-synuclein, and other proteins that play a critical role in the โฆSee details»
Aprinoia | VentureRadar
Aprinoia is developing Tau-PET tracer (18F-APN-1607), currently in phase 3 clinical development in China and phase 2 in the US, for precise diagnosis of various neurodegenerative diseases. โฆSee details»
APRINOIA Therapeutics - Contacts, Employees, Board Members
Organization. APRINOIA Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 8. Number of โฆSee details»
APRINOIA - Company Profile - Tracxn
Nov 29, 2024 APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 (florzolotau) for the Diagnosis of Progressive Supranuclear PalsyBioSpace โข May โฆSee details»
APRINOIA Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial โฆSee details»
APRINOIA Therapeutics Announces Strategic Investment From
Nov 9, 2023 APRINOIA Therapeutics Inc., is a global clinical-stage biopharmaceutical company, headquartered in Cambridge, MA, developing novel therapeutics and precision diagnostics for โฆSee details»
Aprinoia Therapeutics - Overview, News & Similar companies
Aug 28, 2023 APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial BOSTON, April 11, 2022 /PRNewswire/ -- APRINOIA Therapeutics announces โฆSee details»
APRINOIA Therapeutics Inc | Alzheimer's Drug Discovery Foundation
Jul 1, 2023 APRINOIA Therapeutics Inc. Lili Zhang, Ph.D. | Massachusetts, United States ... View all funding to this organization (2) View all funding to this investigator (1) GET IN โฆSee details»
APRINOIA Therapeutics Inc | Alzheimer's Drug Discovery Foundation
Jul 1, 2023 To address this significant unmet need, Aprinoia is developing 18 F-APN-1607 (APN-1607), a new generation PET tracer, that will enable clinicians to visualize tau, an โฆSee details»
EMERGING COMPANY PROFILE APRINOIA TACKLES TAU
Next year, Aprinoia plans to begin U.S. Phase II testing of APN-1607 in AD as well as PSP, for which the tracer has FDA Orphan Drug designation. Aprinoiaโs APN-1701, a third-generation โฆSee details»
Neurology startup to merge with Wilbur Ross-backed SPAC
Jan 18, 2023 The combination of Aprinoia and the SPAC, Ross Acquisition Corp II, will result in a company called Aprinoia Therapeutics Holdings Ltd with an enterprise value of as much as โฆSee details»
APRINOIA Therapeutics and ROSS Acquisition Corp II Announce โฆ
Jan 18, 2023 APRINOIA, incorporated in 2015, is a Cambridge, MA based global clinical-stage biotech company developing novel therapeutics and precision diagnostics for the treatments of โฆSee details»
APRINOIA Therapeutics - Updates, News, Events, Signals & Triggers
APRINOIA Therapeutics announced that its diagnostic drug APN-1607 (florzolotau) has been granted Fast Track designation by the US FDA for the diagnosis of Progressive Supranuclear Palsy. This designation aims to expedite the development and review of drugs intended to treat serious conditions and fill an unmet medical need.See details»
APRINOIA's different Strategy, expanding 'Tau PETโTherapeutics'
Feb 18, 2021 APRINOIA has been focusing on developing tau imaging PET tracers and therapeutics for many years. "Tau is a relatively younger field," said Ming-Kuei Jang. โฆSee details»
Mission, Vision & Core Values of APRINOIA Therapeutics
Oct 2, 2024 APRINOIA Therapeutics is a pioneering biotechnology company committed to revolutionizing the treatment of neurodegenerative diseases through cutting-edge research โฆSee details»
APRINOIA Therapeutics Announces Fast Track Designation
May 22, 2024 APRINOIA Therapeutics Inc. is a clinical-stage biotechnology company, headquartered in Cambridge, MA, committed to developing highly sensitive and selective โฆSee details»